000			03791nam a22005175i 4500
001			978-1-60761-524-8
003			DE-He213
005			20140220084513.0
007			cr nn 008mamaa
008			100316s2010 xxu| s |||| 0|eng d
020			_a9781607615248 _9978-1-60761-524-8
024	7		_a10.1007/978-1-60761-524-8 _2doi
050		4	_aRC254-282
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a616.994 _223
100	1		_aStewart, David J. _eeditor.
245	1	0	_aLung Cancer _h[electronic resource] : _bPrevention, Management, and Emerging Therapies / _cedited by David J. Stewart.
250			_a1st.
264		1	_aTotowa, NJ : _bHumana Press : _bImprint: Humana Press, _c2010.
300			_aXVI, 538p. 30 illus., 14 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCurrent Clinical Oncology
505	0		_aMolecular Pathology of Lung Cancer -- Tumor Microenvironment -- Racial and Ethnic Diversity in Lung Cancer -- Pharmacogenetics of Lung Cancer -- Lung Cancer Prevention -- Adjuvant and Neoadjuvant Therapy of NSCLC -- Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer -- Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment -- Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer -- Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer -- Angiogenesis Inhibitors in Lung Cancer -- Other Molecular Targeted Agents in Non-small Cell Lung Cancer -- Vaccine Therapy for Lung Cancer -- Gene-Based Therapies for Lung Cancer -- Lung Cancer Resistance to Chemotherapy -- Small Cell Carcinoma of the Lung -- Mesothelioma -- Advances in Oncology Clinical Research: Statistical and Study Design Methodologies -- Palliative Care for Patients with Lung Cancer -- The Future of Lung Cancer.
520			_aThis comprehensive resource provides authoritative knowledge of the most up-to-date prevention and treatment strategies for thoracic malignancies. Established and investigational therapies are placed in the context of tumor biology for a full understanding of the pharmacogenetics, etiology, and changing epidemiology of lung cancer. Expert clinicians detail the function of predictive and prognostic factors in the utilization of chemo-radiotherapy, adjuvant and neoadjuvant treatment, and targeted agents. The promises and potential pitfalls of investigational strategies are evaluated with exceptional insight and clarity, with unique attention paid to the mechanisms of drug resistance and targets for lung cancer treatment and prevention. Lung Cancer: Prevention, Management, and Emerging Therapies engages the entire spectrum of therapeutic modalities with focus on systemic approaches. Disease coverage includes newly diagnosed and recurrent non-small cell lung cancer, small cell carcinoma, and mesothelioma. Critical examination of the impact, methodology, and design of clinical trials is presented along with new paradigms for personalized approaches and individual risk assessment.
650		0	_aMedicine.
650		0	_aRadiotherapy.
650		0	_aPneumology.
650		0	_aBiochemistry.
650		0	_aOncology.
650	1	4	_aMedicine & Public Health.
650	2	4	_aOncology.
650	2	4	_aPneumology/Respiratory System.
650	2	4	_aRadiotherapy.
650	2	4	_aMedical Biochemistry.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781607615231
830		0	_aCurrent Clinical Oncology
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-60761-524-8
912			_aZDB-2-SME
999			_c110821 _d110821